What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2026-08-14 compared with 2026-05-07 · 246 added, 193 removed, 196 unchanged (69% of the section changed)

1 unchanged sentence

CONSOLIDATED FINANCIAL STATEMENTS

OF AND FOR THE QUARTER ENDED MARCH 31, 2026

OF AND FOR THE QUARTER ENDED JUNE 30, 2026

CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED):

7 unchanged sentences

CURRENT ASSETS:

Cash and cash

Cash and cash equivalents

Marketable securities

4 unchanged sentences

Long term deposit

Property, plant and equipment,

Operating lease right of

Fund in respect of employee

rights upon retirement

Property, plant and equipment, net

Operating lease right of use assets

Fund in respect of employee rights upon retirement

TOTAL NON-CURRENT ASSETS

CONSOLIDATED BALANCE SHEETS

dollars in thousands other than share and per share data)

dollars in thousands except share and per share data)

LIABILITIES AND EQUITY

1 unchanged sentence

Accounts payable and accruals:

CURRENT LIABILITIES

LONG-TERM LIABILITIES-

Operating lease liabilities

net of current maturities

for employee rights upon retirement and others

TOTAL CURRENT LIABILITIES

LONG-TERM LIABILITIES

COMMITMENTS AND CONTINGENT

Common stock, par value $ 0.0001 per share;

150,000,000 shares authorized at March 31, 2026 and December 31, 2025;

46,838,963 and 43,532,281 shares issued and outstanding at

March 31, 2026 and December 31, 2025, respectively

Preferred C shares, par value $ 0.0001 per

1,172,000 shares authorized at March 31, 2026 and December 31, 2025;

1,718 shares issued and outstanding at March 31, 2026

and December 31 2025

Operating lease liabilities net of current maturities

Liability for employee rights upon retirement and others

TOTAL LONG-TERM LIABILITIES

TOTAL LIABILITIES

COMMITMENTS AND CONTINGENT LIABILITIES

Common stock, par value $ 0.0001

and 150,000,000

shares authorized at June 30, 2026 and December 31, 2025, respectively;

and 43,532,281

shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively

Preferred C shares, par value $ 0.0001 per share;

1,172,000 shares authorized at June 30, 2026 and December 31, 2025;

1,718 shares issued and outstanding at June 30, 2026 and December 31 2025

Additional paid-in capital

liabilities and equity

an amount less than $1 thousand

Accumulated deficit

Total liabilities and equity

Represents an amount less than $1 thousand

accompanying notes are an integral part of the condensed consolidated financial statements.

1 unchanged sentence

dollars in thousands, except share and per share data)

Months Ended March 31,

Three months ended

Six months ended

COST OF REVENUES

GROSS PROFIT (LOSS)

OPERATING EXPENSES:

1 unchanged sentence

Selling and marketing

and administrative

operating expenses

General and administrative

Total operating expenses

LOSS FROM OPERATIONS

FINANCIAL INCOME, net

LOSS PER SHARE - basic and diluted

AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic and diluted

FINANCIAL INCOME (EXPENSE), net:

NET LOSS PER SHARE - basic and diluted

WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic and diluted

accompanying notes are an integral part of the condensed consolidated financial statements.

1 unchanged sentence

dollars in thousands, except share data)

Preferred C shares

Additional paid-in

BALANCE AT January 1, 2025

Exercise of pre-funded

of common stock, included at the market offering net of $ 22 issuance costs

compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 29,295 shares

BALANCE AT March 31,

an amount less than $1 thousand

Exercise of pre-funded warrants **

Issuance of common stock, included at the market offering net of $ 22 issuance costs

Exercise of Warrants Series I to common stock, net of $ 109 issuance costs

Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 288,207 shares

BALANCE AT June 30, 2025

Represents an amount less than $1 thousand

Represents cashless exercise of pre-funded warrants

accompanying notes are an integral part of the condensed consolidated financial statements.

1 unchanged sentence

dollars in thousands, except share data)

Preferred C shares

Additional paid-in

BALANCE AT April 1, 2025

Exercise of pre-funded warrants **

Exercise of Warrants Series I to common stock, net of $ 109 issuance costs

Exercise of Warrants Series I to common stock, net of issuance

Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 258,912 shares

BALANCE AT June 30, 2025

Represents an amount less than $1 thousand

Represents cashless exercise of pre-funded warrants

accompanying notes are an integral part of the condensed consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

dollars in thousands, except share data)

Preferred C shares

Additional paid-in

BALANCE AT January 1, 2026

compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 276,373 shares

compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of shares

BALANCE AT March 31,

an amount less than $1 thousand

Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 336,437 shares

BALANCE AT June 30, 2026

Represents an amount less than $1 thousand

accompanying notes are an integral part of the condensed consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

dollars in thousands, except share data)

Preferred C shares

Additional paid-in

BALANCE AT April 1, 2026

Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 60,064 shares

Share-based compensation related to restricted stock, restricted

stock units and stock options award, net of forfeitures

BALANCE AT June 30, 2026

Represents an amount less than $1 thousand

accompanying notes are an integral part of the condensed consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS

dollars in thousands)

CASH FLOWS FROM OPERATING

Adjustments required to

reconcile net loss to net cash used in operating activities:

Change in fair value of

marketable securities, net of interest received

Change in liability for

employees rights upon retirement

Other financial expenses

Change in operating right

of use asset and operating leasing liability

Share-based compensation

Loss (gains) on amounts

funded in respect of employee rights upon retirement, net

Changes in operating assets

and liability items:

Six months ended

CASH FLOWS FROM OPERATING ACTIVITIES:

Adjustments required to reconcile net loss to net cash used in operating activities:

Change in fair value of marketable securities, net of interest received

Change in liability for employee rights upon retirement

Other financial income

Change in operating right of use asset and operating leasing liability

Share-based compensation expenses

Gains on amounts funded in respect of employee rights upon retirement, net

Changes in operating assets and liability items:

Decrease in prepaid expenses

Increase in trade receivables

Decrease (increase) in

other receivables

(Increase) decrease in

Decrease (increase) in trade receivables

Decrease (increase) in other receivables

Decrease (increase) in inventory

Increase in trade payables

in other payables

cash used in operating activities

CASH FLOWS FROM INVESTING

Purchase of property, plant

and equipment

Investments in marketable

Proceeds from matured marketable

funded in respect of employee rights upon retirement

cash provided by investing activities

CASH FLOWS FROM FINANCING

from issuance of shares

cash provided by financing activities

OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

INCREASE (DECREASE) IN CASH

AND CASH EQUIVALENTS

OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD

OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD

SUPPLEMENT NON-CASH INVESTING

AND FINANCING ACTIVITIES:

Receivable on account of

share issuance

Non-cash purchase of property

and equipment

Increase (decrease) in other payables

Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property, plant and equipment

Investments in marketable securities

Proceeds from matured marketable securities

Amounts funded in respect of employee rights upon retirement

Net cash provided by investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercise of warrants

Proceeds from issuance of shares, net of $ 22 issuance costs

Net cash provided by financing activities

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD

BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD

SUPPLEMENT NON-CASH INVESTING AND FINANCING ACTIVITIES:

Issuance Costs not yet paid

Acquisition of right-of-use assets by means of lease liabilities

Non-cash purchase of property and equipment

accompanying notes are an integral part of the condensed consolidated financial statements.

15 unchanged sentences

countries outside the United States, mainly in Europe, through a network of distributors.

Company’s second product, the CGuard™ Prime Carotid Stent System (“CGuard

Prime”), uses the same stent and MicroNet mesh with a differentiated deployment mechanism.

CGuard Prime received premarket approval (“PMA”) by the U.S.

Food and Drug Administration

(“FDA”) on June 23, 2025, and is marketed exclusively in the United States through

the Company’s direct salesforce.

It also received MDR CE Mark approval on June 12,

to March 31, 2026, the Company announced a voluntary recall in the U.S.

for its CGuard®

Prime 135 cm carotid stent delivery system, initiated in consultation with the FDA.

The Company acted after determining during a controlled launch that the technical success

of the delivery system during carotid artery stenting procedures had not met performance

expectations.

The voluntary action pertained specifically to the CGuard Prime delivery system

and did not include the CGuard stent implant.

The action was strictly voluntary with no implications

to the safety of patients who have previously undergone the procedure to implant a CGuard

connection with the recall, the Company estimates that the reserves to be recognized are approximately

$ 700,000 for customer returns and approximately $ 650,000 for inventory impairment and remediation

Company has an accumulated deficit as of March 31, 2026, as well as a history of net losses and negative operating cash flows.

Company expects to continue incurring losses and negative cash flows from operations until the Company expands its commercial revenue

to a scale that funds its commercial resources, development activities and support functions.

As a result of these expected losses

and negative cash flows from operations, along with the Company’s current cash position, the Company does not have sufficient

resources to fund operations for at least the next 12 months.

Therefore, there is substantial doubt about the Company’s ability

to continue as a going concern.

These financial statements have been prepared assuming that the Company will continue as a going

concern and do not include any adjustments that might result from the outcome of this uncertainty.

In the first quarter of 2026, the Company

submitted a premarket approval (“PMA”) to the U.S.

Food and Drug Administration (“FDA”) for the CGuard EPS.

Company’s second product, the CGuard™ Prime Carotid Stent System (“CGuard Prime”), uses the same stent and MicroNet

mesh with a differentiated deployment mechanism.

CGuard Prime received PMA by the FDA on June 23, 2025.

CGuard Prime also received MDR

CE Mark approval on June 12, 2025.

May 2026, the Company announced a voluntary recall in the U.S.

of CGuard Prime, initiated in consultation with the FDA after the

Company determined during a controlled launch that the technical success rate of its delivery system during CAS procedures did not

meet performance expectations.

The voluntary action was limited to the CGuard Prime delivery system and did not involve the CGuard

stent implant.

The Company’s assessment did not identify new safety concerns for patients who had previously received a CGuard

As of June 30, 2026, substantially all affected products were returned and credits were issued to customers.

recorded approximately $ 734,000 as a reduction of revenue related to these returns.

In addition, the Company recorded

approximately $ 612,000 of inventory impairment associated with the recall.

Company has an accumulated deficit as of June 30, 2026, as well as a history of net losses and negative operating cash flows.

expects to continue incurring losses and negative cash flows from operations until the Company expands its commercial revenue to a scale

that funds its commercial resources, development activities and support functions.

As a result of these expected losses and negative

cash flows from operations, along with the Company’s current cash position, the Company does not have sufficient resources to fund

operations for at least the next 12 months.

Therefore, there is substantial doubt about the Company’s ability to continue as a

going concern.

These financial statements have been prepared assuming that the Company will continue as a going concern and do not include

any adjustments that might result from the outcome of this uncertainty.

On July 17, 2026, the Company received a notification

letter from the Nasdaq Listing Qualifications notifying the Company that it is not in compliance with the minimum bid price

requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

plans include the continued commercialization of the Company’s products and raising capital through the sale of additional

equity securities, debt or capital inflows from strategic partnerships and exercises of warrants.

There are no assurances, however,

that the Company will be successful in obtaining the level of financing needed for its operations.

equity securities, debt or capital inflows from potential strategic partnerships and exercises of warrants.

There are no assurances,

however, that the Company will be successful in obtaining the level of financing needed for its operations.

If the Company is unsuccessful

1 unchanged sentence

Related to the Company’s Operations in Israel

On October 7, 2023, Hamas launched a series of attacks on civilian and military targets in Southern Israel and Central

Israel, to which the Israel Defense Forces responded.

In addition, Iran, Hezbollah and the Houthi movement attacked military and civilian

targets in Israel, to which Israel responded, including through increased air and/or ground operations in Lebanon, Syria, Yemen and Iran.

Following years of conflict in the region, on October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed

to a framework for a ceasefire in Gaza between Israel and Hamas.

On February 28, 2026, the United States and Israel launched joint combat

operations in Iran to which Iran and Hezbollah responded with ballistic missile and drone attacks on Israel as well as other countries

October 7, 2023, Hamas launched a series of attacks on civilian and military targets in Southern Israel and Central Israel, to which

the Israel Defense Forces responded.

In addition, Iran, Hezbollah and the Houthi movement attacked military and civilian targets in Israel,

to which Israel responded, including through increased air and/or ground operations in Lebanon, Syria, Yemen and Iran.

Following years

of conflict in the region, on October 9, 2025, Israel, Hamas, the United States and other countries in the region agreed to a framework

for a ceasefire in Gaza between Israel and Hamas.

On February 28, 2026, the United States and Israel launched joint combat operations

in Iran to which Iran and Hezbollah responded with ballistic missile and drone attacks on Israel as well as other countries and U.S.

military bases in the region.

On April 8, 2026, the United States and Iran agreed to a two-week ceasefire.

How long and how severe

the current conflicts in Gaza, Northern Israel, Lebanon, Iran or the broader region last and become is unknown at this time and any continued

clash among Israel, Hamas, Hezbollah, Iran or other countries or militant groups in the region may escalate in the future into a greater

regional conflict.

The intensity and duration of the security situation in Israel have been difficult to predict, as are the economic

implications on our business and operations and on Israel’s economy in general.

As of the date of these consolidated financial statements,

conflict continues in parts of the region.

The Company’s current manufacturing facility, certain of its key personnel and one of

its offices are located in Israel.

Although the United States and Iran have announced ceasefire and de-escalation arrangements from time to

time, including a memorandum of understanding entered into on June 17, 2026 that contemplates the termination of military operations

on multiple fronts, hostilities have resumed and may continue or escalate.

How long and how severe the current conflicts in Gaza, Northern

Israel, Lebanon, Iran or the broader region last and become is unknown at this time and any continued clash among Israel, Hamas, Hezbollah,

Iran or other countries or militant groups in the region may escalate in the future into a greater regional conflict.

The intensity and

duration of the security situation in Israel have been difficult to predict, as are the economic implications on our business and operations

and on Israel’s economy in general.

As of the date of these condensed consolidated financial statements, conflict continues in

parts of the region.

The Company’s current manufacturing facility, certain of its key personnel and one of its offices are located

At this time, these activities remain largely unaffected.

the three months ended March 31, 2026 and 2025, the impact of this war on the Company’s results of operations and financial

the three and six months ended June 30, 2026 and 2025, the impact of this war on the Company’s results of operations and financial

condition was immaterial, but such impact may increase, which could be material, as a result of the continuation, escalation or expansion

2 unchanged sentences

In the opinion of the Company, the financial statements reflect all adjustments, which include only normal recurring adjustments,

necessary for a fair statement of its financial position as of March 31, 2026, and its results of operations, changes in equity and cash

flows for the three months ended March 31, 2026, and 2025.

These unaudited condensed consolidated financial statements and notes thereto

are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31,

necessary for a fair statement of its financial position as of June 30, 2026, and its results of operations, changes in equity and cash

flows for the three and six months ended June 30, 2026, and 2025.

These unaudited condensed consolidated financial statements and notes

thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December

31, 2025, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 18,

The results of operations for the three months ended March 31, 2026, are not necessarily indicative of results that could be expected

for the entire fiscal year.

The results of operations for the six and three months ended June 30, 2026 are not necessarily indicative of results that could

be expected for the entire fiscal year.

3 - RECENTLY ADOPTED AND ISSUED ACCOUNTING PRONOUNCEMENTS

14 unchanged sentences

ASU to determine its impact on the Company’s consolidated financial statements and disclosures.

In December 2025, the FASB issued ASU 2025-11,

“Interim Reporting (Topic 270) Narrow-Scope Improvements.” The amendments in this Update clarify interim disclosure

requirements and the applicability of Topic 270.

The objective of the update is to provide clarity about current interim

requirements.

The amendments in this update also include a disclosure principle that requires entities to disclose events since the

end of the last annual reporting period that have a material impact on the entity.

The amendments in this ASU are required to be

adopted for interim periods within annual reporting periods beginning after December 15, 2027.

Early adoption is permitted.

Company does not expect ASU 2025-11 to have a material impact on its consolidated financial statements disclosures.

4 – FAIR VALUE MEASUREMENTS

13 unchanged sentences

SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS

of March 31, 2026

As of June 30, 2026

($ in thousands)

Cash equivalents-

Money market funds

Marketable securities-

U.S government bonds

of December 31, 2025

As of December 31, 2025

($ in thousands)

Cash equivalents-

Money market funds

Marketable securities-

2 unchanged sentences

or alternative pricing sources and models utilizing market observable inputs to determine their fair value.

cost of marketable securities as of March 31, 2026, and December 31,2025 is $ 30,227 and $ 45,091 thousand, respectively.

cost of marketable securities as of June 30, 2026, and December 31, 2025, is $ 15,239 and $ 45,091 thousand, respectively.

5 - MARKETABLE SECURITIES

of December 31, 2025, all of the Company’s marketable securities had contractual maturities of less than one year.

table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the three-month periods

ended March 31, 2026, and 2025:

of June 30, 2026, and December 31, 2025, all of the Company’s marketable securities had contractual maturities of less than one

table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the six-month period

ended June 30, 2026, and 2025:

OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES

Six months ended

($ in thousands)

1 unchanged sentence

Interest received

Changes in fair value

during the period

Balance at end of the

Changes in fair value during the period

Balance at end of the period

Capital Stock

of March 31, 2026, the Company had 155,000,000 authorized shares of capital stock, par value $ 0.0001 per share, of which 150,000,000

of June 30, 2026, the Company had 255,000,000 authorized shares of capital stock, par value $ 0.0001 per share, of which 250,000,000

are shares of common stock and 5,000,000 are shares of “blank check” preferred stock.

of March 31, 2026, there were 1,718 shares of Series C preferred stock outstanding, convertible into an aggregate of 7,952 shares

of the Company’s common stock, with a total stated value of $ 10,997 .

of March 31, 2026, there are 43,092,107 outstanding pre-funded warrants.

of March 31, 2026, the Company has outstanding warrants to purchase an aggregate of 25,828,164 shares of common stock as follows:

of June 30, 2026, there were 1,718 shares of Series C preferred stock outstanding, convertible into an aggregate of 7,952 shares of the

Company’s common stock, with a total stated value of $ 10,997 .

of June 30, 2026, there are 43,092,107 outstanding pre-funded warrants.

of June 30, 2026, the Company has outstanding warrants to purchase an aggregate of 25,828,164 shares of common stock as follows:

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK

Exercise price

Expiration date

Series J Warrants

1 unchanged sentence

Total Warrants

* The Series J Warrants

and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series J Warrants, 20 trading days

following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 cm and (B) in the case

on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first

commercial sales of CGuard Prime in the U.S.

Following the commencement of the first commercial sales of CGuard Prime

in the United States, which occurred during the third fiscal quarter of 2025 in July 2025, the Series K Warrants are scheduled to expire

twenty (20) trading days after the end of the fourth fiscal quarter thereafter, which is October 28, 2026.

During the three months ended March 31, 2026, a total of 1,092,344 Series G warrants expired unexercised.

the three months ended March 31, 2026, the Company granted 3,583,055 restricted shares of the Company’s common stock to employees

Series J Warrants and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series J Warrants,

20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 cm and

(B) in the case of the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in

which the first commercial sales of CGuard Prime in the U.S.

Following the commencement of the first commercial sales of CGuard

Prime in the United States, which occurred during the third fiscal quarter of 2025 in July 2025, the Series K Warrants are scheduled

to expire twenty (20) trading days after the end of the fourth fiscal quarter thereafter, which is October 28, 2026.

the six months ended June 30, 2026, a total of 1,092,344 Series G warrants expired unexercised.

the six months ended June 30, 2026, the Company granted 3,725,216 restricted shares of the Company’s common stock to employees

and directors.

3 unchanged sentences

fair value of the above restricted shares was approximately $ 5.8 million.

the three months ended March 31, 2026, the Company granted 1,114,792 restricted stock units convertible into shares of the Company’s

the six months ended June 30, 2026, the Company granted 1,114,792 restricted stock units convertible into shares of the Company’s

common stock to the Company’s chief executive officer.

The restricted stock units are subject to a three-year vesting period,

with one-third of such awards vesting each year, subject to continued service.

fair value of the above restricted share units was approximately $ 1.8 million.

The restricted stock units are subject to a three-year vesting period, with

one-third of such awards vesting each year, subject to continued service.

fair value of the above restricted stock units was approximately $ 1.8 million

7 – RELATED PARTIES TRANSACTIONS

the three months ended March 31, 2025, administrative services provided by a member of the chief executive officer’s immediate

the three and six months ended June 30, 2025, administrative services provided by a member of the chief executive officer’s immediate

family in connection with the Company’s expansion to the U.S.

amounted to $ 24 thousand.

The engagement with the related party was

terminated in July 2025.

amounted to $ 24 and $ 48 thousand, respectively.

The engagement with

the related party was terminated in July 2025.

8 - NET LOSS PER SHARE :

8 unchanged sentences

total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock

units and Series C preferred stock, which were excluded from the calculations of diluted loss per share were 39,285,493 shares and 52,233,293

shares for the three-month period ended March 31, 2026 and 2025, respectively.

This amount includes unvested restricted stock included

in the number of issued and outstanding shares in the amounts of 7,315,673 and 5,671,612 as of March 31, 2026, and 2025, respectively.

the three months ended March 31, 2026, and 2025, the weighted average number of common stock used in computing net loss per share - basic

and diluted was as follows:

units and Series C preferred stock, which were excluded from the calculations of diluted loss per share were 38,356,174 and 49,201,359

for the six and three-month periods ended June 30, 2026 and 2025, respectively.

This amount includes 6,734,737 and 5,456,724 of unvested

restricted stock included in the number of issued and outstanding shares as of June 30, 2026 and

2025, respectively.

the six and three months ended June 30, 2026, and 2025, the weighted average number of common stock used in computing net loss per share

- basic and diluted was as follows:

OF WEIGHTED AVERAGE NUMBER OF SHARES

Three months ended

Six months ended

Weighted average number of common stock

1 unchanged sentence

Weighted average Pre-funded Warrants

Total Weighted average

number of common stock used in computing net loss per share - basic and diluted

Total Weighted average number of common stock used in computing net loss per share - basic and diluted

9 - FINANCIAL INSTRUMENTS :

value of financial instruments

As of March 31, 2026, and December 31, 2025,

the carrying amounts of accounts payable, accounts receivable and other receivables approximate their fair values due to the short-term

maturities of these instruments.

The carrying amount of the long-term deposit

approximates its fair value since it is measured at its present value applying prevailing interest rates.

of March 31, 2026, and December 31, 2025, the allowance for expected credit loss was immaterial.

of June 30, 2026, and December 31, 2025, the carrying amounts of accounts payable, accounts receivable and other receivables approximate

their fair values due to the short-term maturities of these instruments.

carrying amount of the long-term deposit approximates its fair value since it is measured at its present value applying prevailing interest

of June 30, 2026, and December 31, 2025, the allowance for expected credit loss was immaterial.

10- INVENTORY :

4 unchanged sentences

Raw materials and supplies

Total inventory

Company recorded approximately $ 612

thousand of inventory impairment in connection with the voluntary

recall during the six months ended June 30, 2026.

11 - ACCOUNTS PAYABLE AND ACCRUALS - OTHER :

6 unchanged sentences

Current Operating lease liabilities

Customer credit balances *

Payable and Accruals - Other

* Customer credit

balances primarily represent credits issued to customers in connection with the voluntary recall of CGuard Prime products (see note 1a).

12 - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES :

2 unchanged sentences

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS

Three months ended

Six months ended

($ in thousands)

* Other countries

don’t exceed 10% in the three months ended March 31, 2026, and 2025.

do not exceed 10% in the six and three months ended June 30, 2026 and 2025.

** Approximately $ 734 thousand of credits issued in connection with the voluntary

recall were deducted from U.S revenues for the three and six months ended June 30, 2026, which resulted in negative net revenues in the United States for the three months ended June 30 (see note 1a).

principal customers (part of revenues):

OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS

Sales percentage

Three months ended

Six months ended

13 - SEGMENT INFORMATION

Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery

The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery

disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform.

5 unchanged sentences

the CODM examines the clinical trials expenses within the research and development operations.

SCHEDULE OF SEGMENT REVENUE

months ended March 31,

OF SEGMENT REVENUE

Three months ended

Six months ended

Cost of Revenues:

1 unchanged sentence

Other cost of revenues

Inventory write-off

Total Cost of Revenues

Research and development

Research and development (R&D)

Payroll and Benefits

6 unchanged sentences

Total Selling and marketing

General and administrative

General and administrative (G&A)

Payroll and Benefits

1 unchanged sentence

Total General and administrative

Financial Income, net;

Financial Income (expenses), net;

Segment net loss

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements